Actively Enrolling Phase News Today

Agios Presents Updated PYRUKYND® (mitapivat) Data

December 11, 2022

– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependent α- or...

Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND (mitapivat) in Non-transfusion-dependent α- and β-Thalassemia

August 11, 2022

12.08.2022 - – In Adults with Non-transfusion-dependent α- or β-Thalassemia, PYRUKYND Induced ≥1.0 g/dL Hemoglobin Increase from Baseline in 16 of 20 (80%) Patients Between Weeks 4-12 – – PYRUKYND Safety Profile Consistent with Label for FDA-approved Indication ... Seite 1

United Kingdom Kevin Kuo Sarah Gheuens University Of Toronto European Hematology Association Agios Pharmaceuticals Inc

Source: wallstreet-online.de

Navigation

Actively Enrolling Phase News Today

Agios Presents Updated PYRUKYND® (mitapivat) Data

Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND (mitapivat) in Non-transfusion-dependent α- and β-Thalassemia

Explore More Categories

Navigation

Actively Enrolling Phase News Today

Agios Presents Updated PYRUKYND&#xAE; (mitapivat) Data

Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND (mitapivat) in Non-transfusion-dependent &#x3B1;- and &#x3B2;-Thalassemia

Explore More Categories

Agios Presents Updated PYRUKYND® (mitapivat) Data

Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND (mitapivat) in Non-transfusion-dependent α- and β-Thalassemia